



Flow diagram of included studies.



Risk of bias graph. Review authors' judgement about each risk of bias item presented as proportions across all included studies



Literature search in Medline Database via Ovid performed: 21. June 2017 up-dated 11. January 2019.

ID	Search	Results
1	exp Affective Disorders, Psychotic/	2253
2	exp Bipolar Disorder/	36966
3	exp Delusions/	7440
4	exp Depressive Disorder, Major/	25551
5	exp Psychotic Disorders/	48324
6	exp Schizophrenia/	97949
7	(((affective or mental*) adj3 (disorder* or ill*)) or (bipolar adj3 (disorder* or illness* or depress*)) or ((severe* or unipolar or major or manic) adj3 depress*) or mania* or psychoses or psychosis or psychotic or schizo* or delusion*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]	461089
8	1 or 2 or 4 or 5 or 6 or 7	461178
9	exp Employment, Supported/	1073
10	exp Rehabilitation, Vocational/	9980
11	9 or 10	9980
12	(((supported adj3 employment*) or (vocational adj3 (recover* or rehabilitation* or retraining)) or (occupational adj3 (recover* or rehabilitation* or retraining)) or (individual* adj3 placement adj3 support*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]	11805
13	11 or 12	11805
14	8 and 13	2872
15 ¹	(((singl* or doubl* or treb* or tripl*) adj (blind*3 or mask*3)) or (allocated adj2 random)).tw. or (clin* adj25 trial*).ti,ab. or (clinic* adj trial*1).tw. or (double-blind* or random*).af. or clinical trial.pt. or clinical trials as topic.sh. or controlled clinical trial.pt. or double blind method.sh. or single blind method.sh. or double-blind method.sh. or single-blind method.sh. or drug therapy.fs. or exp clinical trials as topic/ or exp research design/ or placebo*.tw. or placebos.sh. or practice guideline.pt. or random allocation.sh. or random*.tw. or random.af. or randomized controlled trial.pt. or randomized controlled trials as topic.sh. or randomized.ab. or randomly allocated.tw. or randomly.ab. or single-blind method.sh. or trial.ab. or trial.ti.) not (case report.tw. or letter.pt. or historical article.pt. or review of reported cases.pt. or multicase review.pt.)	3347555
16	14 and 15	495




Note ¹The filter for randomized controlled trials is from: http://videncentret.dk/Forskertservice/Soegefiltre?sc_lang=en

















































Study characteristics of the eight trails included in the review.

Author/Year	Population	Interventions	Outcomes	Results
Mueser et al. 2004 ³⁰	n=204 Male=62% Schizophrenia or Schizoaffective=75%, Bipolar disorder=5%, Major depression=17%, Others=3%	I: IPS C1: Psychosocial intervention C2: Treatment as usual	Self-esteem Quality of life Psychiatric symptoms Global assessment of functioning	No difference between groups on any of the outcomes.
Bond et al. 2007 ²⁶ /Kukla et al. 2013 ²⁹	n=187, Male=64%, Schizophrenia spectrum=56%, Affective disorder=41%, Other=3%	I: IPS C: Diversified Placement approach	Psychiatric symptoms	No difference between groups on any of the outcomes.
Michon et al 2014 ¹⁶	n=151, Male=74%, Psychotic disorder=59% Other=41%	I: IPS C: Traditional vocational rehabilitation	Self-esteem Quality of life Psychiatric symptoms	No significant differences between groups. Significant improvements for all outcomes in those who were competitively employed at or before follow-up
Drake et al. 1999 ²⁷	n=152, Male=39%, Schizophrenia spectrum=67%, Bipolar=14%, Depression=17%, Other=2%	I: IPS C: EVR (enhanced vocational rehabilitation)	Self-esteem Global assessment of functioning Psychiatric symptoms	No difference between groups on any of the outcomes.
Kin Wong et al. 2008 ²⁸	n=92, Male=59%, Schizophrenia spectrum=70%, Affective disorder=19%, Other=11%	I: IPS C: Conventional rehabilitation program	Quality of life Psychiatric symptoms	No difference between groups on any of the outcomes.
Burns et al. 2007 ²⁴ / Burns et al. 2009 ²³	n=312, Male=60%, Schizophrenia spectrum=80%, Bipolar disorder=17%, Other=3%	I: IPS C: Traditional vocational services	Quality of life Psychiatric symptoms Global assessment of functioning (symptoms)	No difference between groups on any of the outcomes. Significant differences in all measures apart from anxiety,

			Global assessment of functioning (disability)	positive symptoms and depression in those who were competitively employed at or before follow-up
Areberg et al. 2013 ²² / Bejerholm et al. 2015 ²⁵	n=120, Male=56%, Schizophrenia spectrum=65%, Bipolar disorder=7%, Others=28	I: IPS C: Traditional vocational rehabilitation	Empowerment Quality of life Psychiatric symptoms	No difference between groups on any of the outcomes.
Christensen et al 2019 ³¹	n=720, Male=61%, Schizophrenia spectrum=77%, Affective disorder=23%	I: IPS C: Traditional vocational rehabilitation	Self-esteem Quality of life Psychiatric symptoms Global assessment of functioning	No difference between groups on any of the outcomes.

Risk of bias summary: review authors' judgements about each risk of bias item for each study included.

 Low risk of bias
  Unclear risk of bias
  High risk of bias

	Sequence generation	Allocation concealment	Blinding of outcome assessors	Incomplete outcome data	Selective outcome data	Other bias
Areberg 2013 ²² / Bejerholm 2015 ²⁵						
Bond 2007 ²⁶ /Kukla 2013 ²⁹						
Burns 2007 ²⁴ /2009 ²³						
Christensen 2019 ³¹						
Drake 1999 ²⁷						
Michon 2014 ¹⁶						
Mueser 2004 ³⁰						
Kin Wong 2008 ²⁸						

Scales used by trials providing data for meta-analyses and pooled analyses.

	Self-esteem	Empowerment	Quality of life	Symptoms	Level of functioning
Areberg 2013 ²² / Bejerholm 2015 ²⁵		Empowerment Scale (ES)	The Manchester Short Assessment of Quality of Life version 2 (MANSA)	The Brief Psychiatric Rating Scale (BPRS)	
Bond 2007 ²⁶ / Kukla 2013 ²⁹			Abbreviated Version of Lehman's Quality of Life Interview	Positive and Negative Symptom Scale (PANSS)	
Burns 2007 ²⁴ /2009 ²³	Rosenberg Self-Esteem Scale (RSE scale)		Lancashire Quality of Life Profile – European Version: (LQoLP-EU)	Positive and Negative Symptom Scale (PANSS), Hospital Anxiety and Depression Scale (HADS)	Global Assessment of Functioning – symptoms (GAF-S), Global Assessment of Functioning – Disability (GAF-D)
Christensen 2019 ³¹	Rosenberg Self-Esteem Scale (RSE scale)	Empowerment Scale (ES)	Short-Form Health Survey (SF12)	Scale for the Assessment of Negative Symptoms (SANS), Scale for the Assessment of Positive Symptoms (SAPS), Hamilton depression scale (Ham D6)	Global Assessment of functioning – function (GAF-F)
Michon 2014 ¹⁶	Rosenberg Self-Esteem Scale (RSE scale)		The Manchester Short Assessment of Quality of Life version 2 (MANSA)	Mental health inventory-5	
Mueser. 2004 ³⁰	Rosenberg Self-Esteem Scale (RSE scale)		Brief Version of the Quality of Life Interview	Positive and Negative Symptom Scale (PANSS)	Global Assessment Scale (GAS)

Associations between weeks in employment and personal and clinical recovery adjusted for IPS.

	SMD	CI	p-value
Self esteem			
< median weeks	0.14	-0.01,0.30	0.065
≥ median weeks	0.17	0.00,0.35	0.049
Empowerment			
< median weeks	0.18	-0.02,0.37	0.083
≥ median weeks	0.25	0.06,0.44	0.011
Quality of Life			
< median weeks	0.03	-0.16,0.22	0.768
≥ median weeks	0.34	0.14,0.54	0.001
Psychotic symptoms			
< median weeks	0.02	-0.12,0.16	0.758
≥ median weeks	-0.11	-0.27,0.04	0.143
Negative symptoms			
< median weeks	-0.25	-0.40,-0.09	0.002
≥ median weeks	-0.41	-0.56,-0.26	0.000
Anxiety			
< median weeks	-0.02	-0.28,0.23	0.853
≥ median weeks	-0.01	-0.28,0.26	0.936
Level of functioning			
< median weeks	0.23	0.07,0.39	0.005
≥ median weeks	0.59	0.42,0.77	0.000
Depression			
	Log. Reg. coeff.		
< median weeks	-0.45	-0.91,-0.00	0.049
≥ median weeks	-0.61	-1.09,-0.13	0.012

Note: < median. weeks: less than median weeks of employment;> median weeks: more than median weeks of employment.

